These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1176 related articles for article (PubMed ID: 8639594)

  • 1. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
    Lai Z; McCulloch J; Lashuel HA; Kelly JW
    Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer.
    Palaninathan SK; Mohamedmohaideen NN; Snee WC; Kelly JW; Sacchettini JC
    J Mol Biol; 2008 Oct; 382(5):1157-67. PubMed ID: 18662699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
    Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
    J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting the inter-peptide arrangement and maturation process of transthyretin (105-115) amyloid fibril using a FRET pair with short Förster distance.
    Deng W; Cao A; Lai L
    Biochem Biophys Res Commun; 2007 Oct; 362(3):689-94. PubMed ID: 17761149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
    Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
    Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA; Wurth C; Woo L; Kelly JW
    Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.
    Pasquato N; Berni R; Folli C; Alfieri B; Cendron L; Zanotti G
    J Mol Biol; 2007 Feb; 366(3):711-9. PubMed ID: 17196219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomy of an amyloidogenic intermediate: conversion of beta-sheet to alpha-sheet structure in transthyretin at acidic pH.
    Armen RS; Alonso DO; Daggett V
    Structure; 2004 Oct; 12(10):1847-63. PubMed ID: 15458633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.
    Yang M; Yordanov B; Levy Y; Brüschweiler R; Huo S
    Biochemistry; 2006 Oct; 45(39):11992-2002. PubMed ID: 17002298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
    Hurshman AR; White JT; Powers ET; Kelly JW
    Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different disease-causing mutations in transthyretin trigger the same conformational conversion.
    Steward RE; Armen RS; Daggett V
    Protein Eng Des Sel; 2008 Mar; 21(3):187-95. PubMed ID: 18276611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro.
    McCutchen SL; Kelly JW
    Biochem Biophys Res Commun; 1993 Dec; 197(2):415-21. PubMed ID: 8267575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
    Zhang Q; Kelly JW
    Biochemistry; 2003 Jul; 42(29):8756-61. PubMed ID: 12873136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
    Colon W; Kelly JW
    Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
    Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
    Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.